About this Research Topic
Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells involves mechanisms like cancer immune surveillance and immunoediting, fostering a tumor immune microenvironment conducive to growth, survival, proliferation, and metastasis. Immune checkpoint inhibitors (ICIs), despite their effectiveness, present significant side effects and high costs. Another emerging focus is on immunometabolism or immunometabolic reprogramming (IR), which is critical in modulating immune cell functions and phenotypes. Given this backdrop, investigating the relationship between ICIs and IR, and how altering one could impact the other, opens new avenues for enhancing cancer immunotherapy.
This Research Topic aims to concentrate on exploring ICIs and immunometabolism within the tumor immune microenvironment (TIME) and improving the efficacy of current ICIs by leveraging immunometabolic reprogramming. By reducing the immune-related and endocrine toxicities, these approaches represent a prospective advancement in oncologic treatments. Targeted readers are oncologists and immunologists specializing in cancer immunotherapy, particularly those new to the immunometabolic concepts introduced to oncology by pioneers like Otto Warburg, who identified altered metabolism in cancer cells over a century ago.
To deepen our understanding in this area, this Research Topic will accept contributions across various article types, including Commentaries, Original Research, Review articles, and Perspectives and Opinions. We aim to deal with a range of themes, including:
o Current applications and the status of ICIs in cancer therapy,
o Relationships between cancer cell metabolism and immune checkpoint regulation,
o Immunometabolic reprogramming within the TIME,
o The interaction between immunometabolic changes and immune checkpoints,
o Strategies to enhance ICI efficacy through targeted immunometabolic reprogramming. The exploration of various immune checkpoints like PD-1, PD-L1, and CTLA-4 in the context of their expression and functionality will be central to these discussions.
Note that John Stewart IV sits in the scientific Advisory Board of AmmunBio. Additionally, please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
This Research Topic aims to concentrate on exploring ICIs and immunometabolism within the tumor immune microenvironment (TIME) and improving the efficacy of current ICIs by leveraging immunometabolic reprogramming. By reducing the immune-related and endocrine toxicities, these approaches represent a prospective advancement in oncologic treatments. Targeted readers are oncologists and immunologists specializing in cancer immunotherapy, particularly those new to the immunometabolic concepts introduced to oncology by pioneers like Otto Warburg, who identified altered metabolism in cancer cells over a century ago.
To deepen our understanding in this area, this Research Topic will accept contributions across various article types, including Commentaries, Original Research, Review articles, and Perspectives and Opinions. We aim to deal with a range of themes, including:
o Current applications and the status of ICIs in cancer therapy,
o Relationships between cancer cell metabolism and immune checkpoint regulation,
o Immunometabolic reprogramming within the TIME,
o The interaction between immunometabolic changes and immune checkpoints,
o Strategies to enhance ICI efficacy through targeted immunometabolic reprogramming. The exploration of various immune checkpoints like PD-1, PD-L1, and CTLA-4 in the context of their expression and functionality will be central to these discussions.
Note that John Stewart IV sits in the scientific Advisory Board of AmmunBio. Additionally, please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: Cancer; Cancer cell metabolism; Immunometabolism; Immune checkpoints; Immune checkpoint inhibitors; Tumor immune microenvironment (TIME)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
